肺癌患者血清多效蛋白表达水平及其临床意义

doi:10.3877/cma.j.issn.1674-6902.2017.03.010

目的

探讨血清多效蛋白(PTN)在肺癌患者中的表达及其临床意义。

方法

采用ELISA检测57例非小细胞肺癌(NSCLC)患者、20例小细胞肺癌(SCLC)患者和12例正常对照组血清PIN水平，分析其对肺癌的诊断价值及与NSCLC病理分期和手术的关系。

结果

正常对照组PTN水平明显低于SCLC组(P<0.001)和NSCLC组(P＝0.003)，并且SCLC组PTN水平显著高于NSCLC组(P＝0.010)。ROC曲线分析PTN对肺癌诊断的AUC为0.821(95%CI 0.730～0.913)(P<0.001)；对NSCLC诊断的AUC为0.794(95%CI 0.684～0.904)(P＝0.001)；对SCLC诊断的AUC为0.900(95%CI 0.783～1.000)(P<0.001)。NSCLC患者PTN水平与病理分期(P<0.001)和肿瘤远处转移(P＝0.019)密切相关，与病理类型和淋巴结转移无关(P>0.05)。NSCLC患者手术后PTN水平较手术前明显降低(P<0.001)。

结论

血清PTN可作为诊断肺癌的指标，PTN还可用于NSCLC病情监测和疗效判断。

关键词: 多效蛋白, 支气管肺癌, 诊断, 临床意义

Objective

To investigate the serum levels and clinical significance of the angiogenic factor pleiotrophin (PTN) in patients with lung cancer.

Methods

Enzyme-linked immunosorbent assay (ELISA) was used to detect the serum levels of PTN in 57 patients with non-small cell lung cancer (NSCLC), 20 patients with small cell lung cancer (SCLC) and 12 healthy individuals, and their relationship with pathological stage and operation therapy foe NSCLC was explored.

Results

PTN expression was significantly lower in healthy individuals than that in SCLC (P<0.001) and NSCLC patients (P=0.003). PTN level was significantly higher in SCLC patients than that in NSCLC patients (P=0.010). High expression of PTN was identified as a moderately specific marker for lung carcinoma distinguished from healthy subjects with the area under the ROC curve (AUC) at 0.821(95%CI 0.730~0.913) (P<0.001). Additionally, PTN was identified as a lowly specific marker for NSCLC distinguished from healthy subjects with AUC at 0.794 (95%CI 0.684~0.904) (P=0.001). However, PTN was identified as a highly specific marker for SCLC distinguished from healthy subjects with AUC at 0.900 (95%CI 0.783~1.000) (P<0.001). The PTN level in NSCLC patients was significantly associated with clinical stage (P<0.001) and distant metastasis (P=0.019). No association was found between PTN and other clinic pathological features such as pathological type and lymphatic metastasis in NSCLC patients. Compared with NSCLC patients before opertion, PTN level in NSCLC patients after operation was significantly decreased(P<0.001).

Conclusion

PTN in serum has the important values of diagnosing lung cancer. Moreover, PTN in serum can be available to estimate condition and curative effects of NSCLC.

Key words: Pleiotrophin, Bronchiogenic lung cancer, Diagnosis, Clinical significance

图1 肺癌患者和正常对照血清PTN水平柱状图

图2 血清PTN诊断肺癌的ROC曲线图；注：A:血清PTN诊断肺癌的ROC曲线图和AUC；B：血清PTN诊断NSCLC的ROC曲线图和AUC；C：血清PTN诊断SCLC的ROC曲线图和AUC。

表1 NSCLC患者PTN水平与临床参数间的关系(±s)

临床资料		例数	PTN(μg/L)	P值^ab
病理类型		?	?	0.848
?	肺腺癌	35	35.41±12.38	?
?	肺鳞癌	22	31.92±12.65	?
病理分期		?	?	0.000
?	Ⅰ期	11	21.59±9.14	?
?	Ⅱ期	25	30.34±12.73	?
?	Ⅲ期	14	42.32±6.18	?
?	Ⅳ期	7	42.94±7.36	?
淋巴结转移		?	?	0.368
?	无	12	29.34±9.10	?
?	有	45	35.20±13.00	?
远处转移		?	?	0.019
?	无	50	32.22±13.15	?
?	有	7	40.97±6.07	?

表1 NSCLC患者PTN水平与临床参数间的关系(±s)

临床资料		例数	PTN(μg/L)	P值^ab
病理类型		?	?	0.848
?	肺腺癌	35	35.41±12.38	?
?	肺鳞癌	22	31.92±12.65	?
病理分期		?	?	0.000
?	Ⅰ期	11	21.59±9.14	?
?	Ⅱ期	25	30.34±12.73	?
?	Ⅲ期	14	42.32±6.18	?
?	Ⅳ期	7	42.94±7.36	?
淋巴结转移		?	?	0.368
?	无	12	29.34±9.10	?
?	有	45	35.20±13.00	?
远处转移		?	?	0.019
?	无	50	32.22±13.15	?
?	有	7	40.97±6.07	?

表2 手术前后血清PTN水平变化(±s)

组　别	例数	PTN(μg/L)
手术前	48	34.07±12.49
手术后	48	28.58±8.78^a
t值	?	－7.004
P值	?	0.000

表2 手术前后血清PTN水平变化(±s)

组　别	例数	PTN(μg/L)
手术前	48	34.07±12.49
手术后	48	28.58±8.78^a
t值	?	－7.004
P值	?	0.000

1	钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版) , 2011, 4(1): 1-6.
2	任成山，白莉，钱桂生. 慢性阻塞性肺疾病合并肺癌临床特征及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2015, 8(2): 137-142.
3	张红军，顾兴，刘伟，等. 肿瘤标志物动态变化在肺癌疗效判断与随访中的意义[J/CD]. 中华肺部疾病杂志(电子版), 2016, 9(1):26-30.
4	王会中，任成山，金发光. 肿瘤生物标志物在肺癌患者检测中的临床意义及研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2016, 9(3):329-333.
5	Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63 (1): 11-30.
6	王春香，王剑，张明，等. 肺癌患者血浆MGMT基因异常甲基化检测方法的初步研究和临床意义[J/CD]. 中华肺部疾病杂志(电子版), 2010, 3 (3): 162-166.
7	刘洎，林波，李克. CUB结构域蛋白1在肺癌中的表达及临床意义[J]. 中华实用诊断与治疗杂志，2015, 29(1): 41-43.
8	Papadimitriou E, Mikelis C, Lampropoulou E, et al. Roles of pleiotrophin in tumor growth and angiogenesis[J]. Eur Cytokine Netw, 2009, 20(4): 180-190.
9	Yao J, Ma Q, Wang L, et al. Pleiotrophin expression in human pancreatic cancer and its correlation with clinicopathological features, perineural invasion, and prognosis[J]. Dig Dis Sci, 2009, 54(4): 895-901.
10	Yao J, Hu XF, Feng XS, et al. Pleiotrophin promotes perineural invasion in pancreatic cancer[J]. World J Gastroenterol, 2013, 19(39): 6555-6558.
11	Tsirmoula S, Dimas K, Hatziapostolou M, et al. Implications of pleiotrophin in human PC3 prostate cancer cell growth in vivo[J]. Cancer Sci, 2012, 103(10): 1826-1832.
12	Kong Y, Bai PS, Nan KJ, et al. Pleiotrophin is a potential colorectal cancer prognostic factor that promotes VEGF expression and induces angiogenesis in colorectal cancer[J]. Int J Colorectal Dis, 2012, 27(3): 287-298.
13	Peria FM, Neder L, Marie SK, et al. Pleiotrophin expression in astrocytic and oligodendroglial tumors and it′s correlation with histological diagnosis, microvascular density, cellular proliferation and overall survival[J]. J Neurooncol, 2007, 84(3): 255-261.
14	Chang Y, Zuka M, Perez-Pinera P, et al. Secretion of pleiotrophin stimulates breast cancer progression through remodeling of the tumor microenvironment[J]. Proc Natl Acad Sci USA, 2007, 104(26): 10888-10893.
15	Wu H, Barusevicius A, Babb J, et al. Pleiotrophin expression correlates with melanocytic tumor progression and metastatic potential[J]. J Cutan Pathol, 2005, 32(2): 125-130.
16	Jäger R, List B, Knabbe C, et al. Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients[J]. Br J Cancer, 2002, 86(6): 858-863.
17	Feng ZJ, Gao SB, Wu Y, et al. Lung cancer cell migration is regulated via repressing growth factor PTN/RPTP β/ζ signaling by menin [J]. Oncogene, 2010, 29(39): 5416-5426.
18	Mikelis C, Lamprou M, Koutsioumpa M, et al. A peptide corresponding to the C-terminal region of pleiotrophin inhibits angiogenesis in vivo and in vitro[J]. J Cell Biochem, 2011, 112(6): 1532-1543.
19	Souttou B, Juhl H, Hackenbruck J, et al. Relationship between serum concentrations of the growth factor p leiotrophin and pleiotrophin2positive tumors[J]. J Natl Cancer Inst, 1998, 90(19): 1468-1473.
20	Rosenfield SM, Bowden ET, Cohen-Missner S, et al. Pleiotrophin(PTN) expression and function and in the mouse mammary gland and mammary epithelial cells[J]. PLoS One, 2012, 7(10): e47876.

[1]	杨水华, 何桂丹, 覃桂灿, 梁蒙凤, 罗艳合, 李雪芹, 唐娟松. 胎儿孤立性完全型肺静脉异位引流的超声心动图特征及高分辨率血流联合时间-空间相关成像的应用[J]. 中华医学超声杂志（电子版）, 2023, 20(10): 1061-1067.
[2]	蒋佳纯, 王晓冰, 陈培荣, 许世豪. 血清学指标联合常规超声及超声造影评分诊断原发性干燥综合征的临床价值[J]. 中华医学超声杂志（电子版）, 2023, 20(06): 622-630.
[3]	谭巧, 苏小涵, 侯令密, 黎君彦, 邓世山. 乳腺髓样癌的诊治进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 366-368.
[4]	杨小菁, 姜瑞瑞, 石玉香, 王静静, 李长天. 乳腺孤立性纤维性肿瘤一例[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 375-377.
[5]	冯雪园, 韩萌萌, 马宁. 乳腺原发上皮样血管内皮瘤一例[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 378-380.
[6]	彭旭, 邵永孚, 李铎, 邹瑞, 邢贞明. 结肠肝曲癌的诊断和外科治疗[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 108-110.
[7]	李智铭, 郭晨明, 庄晓晨, 候雪琴, 高军喜. 早期乳腺癌超声造影定性及定量指标的对比研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 639-643.
[8]	杨雪, 张伟, 尚培中, 宋创业, 尚丹丹, 张蔚. 胆囊十二指肠瘘结石经瘘口排出后自愈一例报道[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 707-708.
[9]	顾睿祈, 方洪生, 蔡国响. 循环肿瘤DNA检测在结直肠癌诊治中的应用与进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 453-459.
[10]	赵立力, 王魁向, 张小冲, 李志远. 血沉与C-反应蛋白比值在假体周围感染中的诊断价值分析[J]. 中华老年骨科与康复电子杂志, 2023, 09(06): 351-355.
[11]	吴凤芸, 滕鑫, 刘连娟. 高帧频超声造影与增强磁共振对不同直径原发性高分化肝细胞癌的诊断价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 404-408.
[12]	孙欣欣, 刘军, 陈超伍, 孙超. 超声内镜引导细针穿刺抽吸术在胰腺占位性病变中的应用[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 418-421.
[13]	袁媛, 赵良平, 刘智慧, 张丽萍, 谭丽梅, 閤梦琴. 子宫内膜癌组织中miR-25-3p、PTEN的表达及与病理参数的关系[J]. 中华临床医师杂志(电子版), 2023, 17(9): 1016-1020.
[14]	李田, 徐洪, 刘和亮. 尘肺病的相关研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 900-905.
[15]	周婷, 孙培培, 张二明, 安欣华, 向平超. 北京市石景山区40岁及以上居民慢性阻塞性肺疾病诊断现状调查[J]. 中华临床医师杂志(电子版), 2023, 17(07): 790-797.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Expression of pleiotrophin in serum and its clinical significance in patients with lung cancer

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Expression of pleiotrophin in serum and its clinical significance in patients with lung cancer